Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

The decision to discontinue primary or secondary prophylaxis for HIV-associated OIs should be made on a case-by-case basis. Continued surveillance and careful monitoring of patients who stop ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at ...

The objective of this study was to examine the effectiveness of register-based and opportunistic chlamydia ... adverse pregnancy outcomes, neonatal infection, chlamydia prevalence) and harms ...

Nocardiosis is caused by various species of Nocardia and typically occurs as an opportunistic infection. It frequently disseminates ... current therapeutic guidelines and the question of prophylaxis ...

Post-exposure prophylaxis (PEP). Chou R ... Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents.

The advent of biological therapy to treat many conditions, including autoimmune diseases, asthma, and even cancer, has changed the prognosis of millions of patients, decreasing morbidity and mortality ...

Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 ...

(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association. Laura M. Mann ...

The primary outcome was a safety event (a composite of death from any cause, graft loss, serious adverse event, HIV breakthrough infection, persistent failure of HIV treatment, or opportunistic ...